Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

France’s Sanofi Pasteur Adopts “High State Of Readiness” To Produce Global Vaccine Defense Arsenal If H1N1 Evolves Into Pandemic: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Immediately after the Director-General of the World Health Organization raised the pandemic alert level from phase 4 to phase 5, just one step below notification of a global health threat, an influenza expert at Sanofi Pasteur outlined the French-based vaccine maker's response: moving into a "high state of readiness" to help create a worldwide vaccine defense to the speedening spread of H1N1. Sanofi Pasteur is a global power in terms of vaccine production, turning out 1.6 billion vaccine doses in 2008, and specialist Albert Garcia at Pasteur's headquarters in Lyon, France provided an overview on how the outfit's operations in the Americas, Europe and Asia could be mobilized in a worldwide fight against H1N1.

Table

View full table

Tags:
Latest Headlines

Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout

Dupixent COPD Approval Could Be Delayed, Regeneron Cautions

Competition Forces Price Cuts, But Novo Nordisk Is Unstoppable

Metagenomi Looks For Upside To Moderna’s Exit

See All
UsernamePublicRestriction

Register

SC071675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By